Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma: Advanced Disease

October 20, 2014

Join Jason Rockhill, MD and John Thompson, MD as they present their multidisciplinary expertise on a range of cases pertaining to advanced disease melanoma.

Treatment of advanced melanoma has entered a new era with the approval of novel immunotherapeutic and targeted agents. Two additional targeted agents—MEK inhibitor trametinib and BRAF inhibitor dabrafenib—have received approval for patients with documented V600 mutation of BRAF based on survival benefits in randomized trials. A new class of upcoming agents targeted against the programmed death -1 (PD-1) receptor (lambrolizumab and nivolumab) also demonstrated durable responses in patients with advanced melanoma, which may further change the landscape of this rapidly evolving field.

Evidence from follow-up studies of vemurafenib and ipilimumab shed light on their use in different clinical settings, drug resistance mechanisms, and side effects management. Research also focused on the sequence and combination of novel drugs. A recent FDA approval was granted to the combination of dabrafenib and trametinib based on improved progression-free survival compared to monotherapy.

In advanced disease, clinicians need to know the prognostic markers prior to deciding on a treatment for the patient. With the advent of targeted therapy, mutation testing has become a critical component in the routine work-up of advanced disease.  Management of adverse events and response to therapy may be different than with traditional chemotherapy. These differences should be discussed with patients prior to beginning therapy with immune-oncology agents.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with advanced disease melanoma
  • Describe the multidisciplinary aspects of the management of patients with  advanced disease melanoma
  • Identify the key characteristics of  advanced disease melanoma that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
Course expires: 
Event starts: 
10/20/2014 - 2:00pm EDT
Event ends: 
10/20/2014 - 3:00pm EDT

Jason Rockhill, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

John Thompson, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing